PT - JOURNAL ARTICLE AU - S Wendel AU - R Fontão-Wendel AU - R Fachini AU - G Candelaria AU - P Scuracchio AU - R Achkar AU - MA Brito AU - LFL Reis AU - A Camargo AU - M Amano AU - RRG Machado AU - D Araujo AU - CP Soares AU - E Durigon TI - Correlation of Body Mass Index (BMI), initial neutralizing antibodies (nAb), ABO group and kinetics of nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibodies in convalescent plasma (CCP) donors – A longitudinal study with proposals for better quality of CCP collections AID - 10.1101/2020.11.12.20230391 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.12.20230391 4099 - http://medrxiv.org/content/early/2020/11/15/2020.11.12.20230391.short 4100 - http://medrxiv.org/content/early/2020/11/15/2020.11.12.20230391.full AB - Introduction A cohort of COVID-19 convalescent volunteers allowed the study of neutralizing (nAb) and ligand antibodies kinetics by providing sequential samples during a median of 100 days after onset of disease.Material and Methods A cohort of previously RT-PCR+ve (detected by nasopharyngeal swab during the acute phase), male convalescent patients, all with mild symptoms, were enrolled on serial blood sample collection for evaluation of longitudinal nAb titers and anti-nucleocapsid (NP) antibodies (IgM, IgG and IgA). Nabs were detected by a cytopathic effect-based virus neutralization test (CPE-based VNT), carried out with SARS-CoV-2 (GenBank: MT350282)Results A total of 78 male volunteers provided 316 samples, spanning a total of 4820 days of study. Although only 25% of donors kept nAb titers ≥160, after a median of 100 days after the onset of disease, there was a high probability of sustaining nAB titers ≥160 in volunteers whose initial nAb titer was ≥1280, weight ≥ 90kg or BMI classified as overweight or obese, evidenced by Kaplan-Meier estimates and Cox hazard regression. There was no correlation between ABO group, ABO antibody titers and persistent high nAb titers. High IgG anti-NP (S/CO ≥5.0) is a good surrogate for detecting nAB ≥160, defined by ROC curve (sensitivity = 90.5%; CI95% 84.5-94.7%)Conclusion Selection of CCP donors for multiple collections based on initial high nAb titers (≥1280) or overweight/obese (BMI) provides a simple strategy to achieve higher quality in CCP programs. High IgG anti-NP levels can also be used as surrogate markers for high nAb screening.Competing Interest StatementCPS is funded by Grant - 2018/23680-0 (FAPESP); DBA by Grant 88887.131387/2016- 00 (CAPES), RRGM by Grant 2017/24769-2 (FAPESP) and ELD by Grants 2016/20045-7 and 2020/06409-1 (FAPESP). This project was partially supported by the initiative Todos Pela Saude.Funding StatementThis project was partially supported by the initiative Todos Pela SaudeAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was approved by our IRB and the Brazilian Commission on Ethics and Research (CONEP) under request CAAE: 30259220.4.2001.5461.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI hereby state that all data will be availabe under special request